Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006792 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-03 | 2022-02-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $243.64 | -526 | 56.0K | -0.9% | -$128.2K | |
| M | 2022-02-03 | 2022-02-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.98 | -1,040 | 55.3K | -2% | -$261.0K |
| M | 2022-02-03 | 2022-02-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | A - Grant | $0.00 | +23.9K | 56.5K | +73% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | F | D | 526 | $243.64 | 55,992 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-02 | S | D | 16 | $254.54 | 54,952 | D | — | — | (F9) Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80). (F5) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2022-02-02 | S | D | 64 | $253.95 | 54,968 | D | — | — | (F8) Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42). (F5) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2022-02-02 | S | D | 149 | $253.07 | 55,032 | D | — | — | (F5) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F7) Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42). |
| 5 | Common | Common Stock | 2022-02-02 | S | D | 141 | $251.47 | 55,181 | D | — | — | (F6) Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85). (F5) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2022-02-02 | S | D | 670 | $250.04 | 55,322 | D | — | — | (F5) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97). |
| 7 | Common | Common Stock | 2022-02-01 | A | A | 11,628 | $0.00 | 44,204 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. |
| 8 | Common | Common Stock | 2022-02-01 | A | A | 12,314 | $0.00 | 56,518 | D | — | — | (F2) Restricted stock unit award that vests in installments beginning on 02/24/2023. |